ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 978,51
0,55%
Dow Jones
38 111,48
-0,86%
DAX
18 496,79
0,12%
Brent Oil
81,745
-0,25%
Bitcoin
68 513,95
0,22%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Oncomed Pharmaceuticals, Inc. (OMED)

  7. Oncomed Pharmaceuticals, Inc. (OMED) Actualités

OMED

ONCOMED PHARMACEUTICALS INC (OMED)

Oncomed Pharmaceuticals, Inc.
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:OMED
DateHeureSourceTitreSymboleSociété
03/05/201922h36Edgar (US Regulatory)Termination of Registration of a Class of Security Under Section 12(b) (15-12b)NASDAQ:OMEDOncomed Pharmaceuticals, Inc.
26/04/201922h53Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:OMEDOncomed Pharmaceuticals, Inc.
24/04/201917h58Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:OMEDOncomed Pharmaceuticals, Inc.
23/04/201922h19Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:OMEDOncomed Pharmaceuticals, Inc.
23/04/201922h18Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:OMEDOncomed Pharmaceuticals, Inc.
23/04/201915h28GlobeNewswire Inc.Mereo BioPharma Group plc ("Mereo" or the "Company" or the "Group") Completion of the Merger with OncoMed Pharmaceuticals, ...NASDAQ:OMEDOncomed Pharmaceuticals, Inc.
23/04/201915h01Edgar (US Regulatory)Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or ...NASDAQ:OMEDOncomed Pharmaceuticals, Inc.
18/04/201908h00GlobeNewswire Inc.Mereo BioPharma Group plc ("Mereo" or the "Company" or the "Group") Merger Update: Acquisition of OncoMed Pharmaceuticals, In...NASDAQ:OMEDOncomed Pharmaceuticals, Inc.
17/04/201921h25Edgar (US Regulatory)Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)NASDAQ:OMEDOncomed Pharmaceuticals, Inc.
20/03/201922h06Edgar (US Regulatory)Proxy Statement - Merger or Acquistion (definitive) (defm14a)NASDAQ:OMEDOncomed Pharmaceuticals, Inc.
15/03/201921h42Edgar (US Regulatory)Statement of Beneficial Ownership (sc 13d)NASDAQ:OMEDOncomed Pharmaceuticals, Inc.
15/03/201912h00GlobeNewswire Inc.OncoMed Pharmaceuticals Declares Special Dividend of Contingent Value RightsNASDAQ:OMEDOncomed Pharmaceuticals, Inc.
07/03/201922h41Edgar (US Regulatory)Annual Report (10-k)NASDAQ:OMEDOncomed Pharmaceuticals, Inc.
07/03/201922h00GlobeNewswire Inc.OncoMed Announces Fourth Quarter and Full Year 2018 Financial ResultsNASDAQ:OMEDOncomed Pharmaceuticals, Inc.
14/02/201923h23Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:OMEDOncomed Pharmaceuticals, Inc.
14/02/201912h59Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:OMEDOncomed Pharmaceuticals, Inc.
05/12/201814h10GlobeNewswire Inc.Proposed Combination of Mereo BioPharma and OncoMed PharmaceuticalsNASDAQ:OMEDOncomed Pharmaceuticals, Inc.
09/11/201814h00GlobeNewswire Inc.OncoMed Announces Early Clinical Data for anti-TIGIT AntibodyNASDAQ:OMEDOncomed Pharmaceuticals, Inc.
01/11/201821h26Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:OMEDOncomed Pharmaceuticals, Inc.
01/11/201821h05GlobeNewswire Inc.OncoMed Announces Third Quarter 2018 Financial Results and Operational HighlightsNASDAQ:OMEDOncomed Pharmaceuticals, Inc.
22/10/201814h00GlobeNewswire Inc.OncoMed Announces Interim Phase 1b Results for Navicixizumab and Paclitaxel Combination Therapy in Platinum-resistant Ovarian...NASDAQ:OMEDOncomed Pharmaceuticals, Inc.
18/10/201801h01Dow Jones NewsOncoMed Says Celgene Won't Exercise Option to License RosmantuzumabNASDAQ:OMEDOncomed Pharmaceuticals, Inc.
09/10/201814h00GlobeNewswire Inc.OncoMed Announces Upcoming Presentation of Navicixizumab Interim Phase 1b Data at the European Society of Clinical Oncology M...NASDAQ:OMEDOncomed Pharmaceuticals, Inc.
24/09/201822h00GlobeNewswire Inc.OncoMed to Present at the Cantor Global Healthcare ConferenceNASDAQ:OMEDOncomed Pharmaceuticals, Inc.
24/09/201814h00GlobeNewswire Inc.OncoMed Announces Publication of Phase 1a Data of NavicixizumabNASDAQ:OMEDOncomed Pharmaceuticals, Inc.
20/09/201814h59Dow Jones NewsOncoMed Says Celgene Won't Exercise Option to License NavicixizumabNASDAQ:OMEDOncomed Pharmaceuticals, Inc.
20/09/201814h00GlobeNewswire Inc.OncoMed Provides Update on Navicixizumab PartnershipNASDAQ:OMEDOncomed Pharmaceuticals, Inc.
29/08/201822h00GlobeNewswire Inc.OncoMed to Present at Two Upcoming Investor Conferences in SeptemberNASDAQ:OMEDOncomed Pharmaceuticals, Inc.
21/08/201822h57Edgar (US Regulatory)Confidential Treatment Order (ct Order)NASDAQ:OMEDOncomed Pharmaceuticals, Inc.
02/08/201814h00GlobeNewswire Inc.OncoMed Announces Second Quarter 2018 Financial Results and Operational HighlightsNASDAQ:OMEDOncomed Pharmaceuticals, Inc.
 Showing the most relevant articles for your search:NASDAQ:OMED

Dernières Valeurs Consultées

BOV
ELET3M
ELETROBRAS ON
BMF
T10M24
T10M24 - Maio 2024
ASX
FCL
FINEOS
BIT
Q00285
Leonteq Securities
TG
X5U
ATHA Energy
BIT
P1GJM4
BNP Paribas Issuance
TG
6CPA
Advantage Solutions
AMEX
APRD
Innovator Premium Income...
LSE
0RSL
Esker
TG
O8S
Premium Nickel Resources
LSE
FB45
Int.fin.24
NASDAQ
PSAI
Pediatric Services OF America
ASX
PMYO
Pacifico Minerals
BOV
PORT3Q
Wilson Sons Holdings Bra... ON
BOV
MWET3
WETZEL ON
EU
CRTO
Touraine et du Poitou CR...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés